The Manila Times

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as ...
STAT

Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. On Wednesday, scientists reported interim results from an early study of ...
The Victoria Advocate

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...
Morningstar

Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis

Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing ...